Is Klotho F352V Polymorphism the Missing Piece of the Bone Loss Puzzle in Renal Transplant Recipients?

Area of Science:

• Nephrology
• Endocrinology
• Genetics

Background:

• Bone disorders are highly prevalent in renal transplant (RT) recipients, second only to cardiovascular issues.
• Reduced levels of 1,25-dihydroxycholecalciferol (1,25D) are a significant factor contributing to bone loss in RT patients.
• Klotho (KL) protein, a co-receptor for FGF23, plays a crucial role in vitamin D metabolism.

Purpose of the Study:

• To investigate the association between the Klotho (KL) F352V polymorphism and 1,25-dihydroxycholecalciferol (1,25D) levels in renal transplant recipients.
• To determine if the KL F352V polymorphism influences vitamin D levels, a key factor in bone health.
• To explore the potential impact of KL F352V polymorphism on bone loss in RT recipients.

Main Methods:

• Genotyping of the KL F352V polymorphism using high-resolution DNA melting analysis.
• Categorization of RT recipients into wild-type (FF) and heterozygous (FV) phenotypes for the KL F352V polymorphism.
• Measurement of serum 1,25D levels via radioimmunoassay (RIA).

Main Results:

• Renal transplant recipients with the FV phenotype exhibited significantly lower serum 1,25D levels compared to those with the FF phenotype.
• Serum 1,25D levels in RT recipients with the FF phenotype were significantly higher than in healthy control subjects.
• The FV phenotype was associated with markedly reduced 1,25D levels (17.58 ± 18.38 pg/ml) versus FF phenotype (44.91 ± 24.68 pg/ml) and controls (28.24 ± 12.13 pg/ml).

Conclusions:

• The KL F352V polymorphism may alter the expression of the FGF23 co-receptor (KL protein), potentially affecting renal 1α-hydroxylase and 24-hydroxylase activity.
• Reduced 1,25D levels resulting from this polymorphism could contribute to the pathogenesis of bone loss in renal transplant recipients.
• This genetic variation represents a potential therapeutic target for managing bone disorders in RT patients.